Research programme: anti-CD160 antibody - ElsaLys Biotech

Drug Profile

Research programme: anti-CD160 antibody - ElsaLys Biotech

Alternative Names: anti-CD160 bispecific antibody -ElsaLys; ELB 011; ELB-012; ELB-021

Latest Information Update: 20 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator INSERM
  • Developer ElsaLys Biotech; INSERM
  • Class Antibodies; Bispecific antibodies
  • Mechanism of Action CD antigen modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Age-related macular degeneration; Chronic lymphocytic leukaemia; Diabetic retinopathy; Glaucoma; Solid tumours

Most Recent Events

  • 18 Jul 2017 ElsaLys Biotech and DKFZ collaborate for preclinical studies for ELB 021 in B-cell leukaemia
  • 02 Feb 2017 Preclinical trials in Chronic lymphocytic leukaemia in France (Parenteral) prior to February 2017 (ElsaLys Biotech's pipeline, February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top